Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
Autonomix Medical, Inc. (AMIX)
Company Research
Source: GlobeNewswire
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source Positive 7-day topline results from first five lead-in patients of the ongoing proof-of-concept (PoC) human clinical trial in pain associated with pancreatic cancer 4–6-week follow-up data expected before end of Q3 CY2024 and topline data from the trial expected 1H CY2025 THE WOODLANDS, TX, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today reported financial results for the first quarter fiscal year 2025 ended June 30, 2024 and provided a corporate update. Recent Highlights Appointed proven medical technology leader, Brad Hauser, as President and Chief Executive Officer;Completed licensing transaction with RF Innovations, Inc., a privately held medical tec
Show less
Read more
Impact Snapshot
Event Time:
AMIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMIX alerts
High impacting Autonomix Medical, Inc. news events
Weekly update
A roundup of the hottest topics
AMIX
News
- Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner SegmentGlobeNewswire
- Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum [Yahoo! Finance]Yahoo! Finance
- Autonomix Selected to Present at the 2024 Octane Medical Innovation ForumGlobeNewswire
- Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain PatientsGlobeNewswire
- Autonomix Medical, Inc. (NASDAQ: AMIX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $1.40 price target on the stock.MarketBeat
AMIX
Sec Filings
- 9/20/24 - Form 8-K
- 9/5/24 - Form DEFA14A
- 9/4/24 - Form DEF
- AMIX's page on the SEC website